Consistently, Franzè et al. pointed out that in patients with IBD treated with mesalazine or corticosteroids or immunomodulators, CD163 RNA expression was not influenced by the ongoing treatments [28]. This evidence concerns the gene CD163 and inflammatory bowel disease.